A pilot randomized, controlled, clinical study assessing the non-inferiority of calcium channel blockade over alpha blockade on hemodynamic stability in the management of Pheochromocytoma/Paraganglioma (PPGL)

A pilot randomized controlled clinical study assessing the non- inferiority of calcium channel blockade over alpha blockade on hemodynamic stability in the management of Pheochromocytoma/Paraganglioma (PPGL)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/06/014604

Enrollment

Registered

2018-06-22

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Pheochromocytoma and Paragangliom

Interventions

Intervention1: Calcium Channel Blockers: For preoperative blocking patient will be admitted and blood pressure monitoring will be done twice daily and SOS as required. All patients will be given preop

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patient with Pheochromocytomas/ paraganglioma (PPGL)

Exclusion criteria

Exclusion criteria: Exclusion criteria: ï?? Pregnant patient ï?? Ongoing immunosuppressive treatment ï?? Psychiatric or other serious diseases ï?? Patients unwillingness to participate in the study ï?? Patient age < 18 yrs

Design outcomes

Primary

Measure	Time frame
Calcium channel blockade is non inferior to alpha blockadeTimepoint: after study completion	—

Secondary

Measure	Time frame
Less post operative hypotensionTimepoint: 2 years	—

Countries

India

Contacts

Public ContactDr Tushar R Bandgar

Seth G S Medical College and KEM Hospital

drtusharb@gmail.com9820025037

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026